Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4)
Identifieur interne : 001B15 ( PascalFrancis/Corpus ); précédent : 001B14; suivant : 001B16Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4)
Auteurs : P. Bertuccio ; C. La Vecchia ; D. T. Silverman ; G. M. Petersen ; P. M. Bracci ; E. Negri ; D. Li ; H. A. Risch ; S. H. Olson ; S. Gallinger ; A. B. Miller ; H. B. Bueno-De-Mesquita ; R. Talamini ; J. Polesel ; P. Ghadirian ; P. A. Baghurst ; W. Zatonski ; E. T. Fontham ; W. R. Bamlet ; E. A. Holly ; E. Lucenteforte ; M. Hassan ; H. Yu ; R. C. Kurtz ; M. Cotterchio ; J. Su ; P. Maisonneuve ; E. J. Duell ; C. Bosetti ; P. BoffettaSource :
- Annals of oncology [ 0923-7534 ] ; 2011.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Background: Cigarette smoking is the best-characterized risk factor for pancreatic cancer. However, data are limited for other tobacco smoking products and smokeless tobacco. Materials and methods: We conducted a pooled analysis of cigar and pipe smoking and smokeless tobacco use and risk of pancreatic cancer using data from 11 case-control studies (6056 cases and 11 338 controls) within the International Pancreatic Cancer Case-Control Consortium (PanC4). Pooled odds ratios (OR) and the corresponding 95% confidence intervals (CI) were estimated by unconditional multiple logistic regression models adjusted for study center and selected covariates. Results: Compared with never tobacco users, the OR for cigar-only smokers was 1.6 (95% CI: 1.2-2.3), i.e. comparable to that of cigarette-only smokers (OR 1.5; 95% CI 1.4-1.6). The OR was 1.1 (95% CI 0.69-1.6) for pipe-only smokers. There was some evidence of increasing risk with increasing amount of cigar smoked per day (OR 1.82 for ≥ 10 grams of tobacco), although not with duration. The OR for ever smokeless tobacco users as compared with never tobacco users was 0.98 (95% CI 0.75-1.3). Conclusion: This collaborative analysis provides evidence that cigar smoking is associated with an excess risk of pancreatic cancer, while no significant association emerged for pipe smoking and smokeless tobacco use.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 11-0317098 INIST |
|---|---|
| ET : | Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4) |
| AU : | BERTUCCIO (P.); LA VECCHIA (C.); SILVERMAN (D. T.); PETERSEN (G. M.); BRACCI (P. M.); NEGRI (E.); LI (D.); RISCH (H. A.); OLSON (S. H.); GALLINGER (S.); MILLER (A. B.); BUENO-DE-MESQUITA (H. B.); TALAMINI (R.); POLESEL (J.); GHADIRIAN (P.); BAGHURST (P. A.); ZATONSKI (W.); FONTHAM (E. T.); BAMLET (W. R.); HOLLY (E. A.); LUCENTEFORTE (E.); HASSAN (M.); YU (H.); KURTZ (R. C.); COTTERCHIO (M.); SU (J.); MAISONNEUVE (P.); DUELL (E. J.); BOSETTI (C.); BOFFETTA (P.) |
| AF : | Department of Epidemiology, Istituto di Ricerche Farmacologiche "Mario Negri/Milan/Italie (1 aut., 2 aut., 6 aut., 29 aut.); Department of Occupational Health, Section of Medical Statistics, University of Milan/Milan/Italie (1 aut., 2 aut.); National Cancer Institute/Bethesda/Etats-Unis (3 aut., 26 aut.); Mayo Clinic/Rochester/Etats-Unis (4 aut., 19 aut.); University of California/San Francisco/Etats-Unis (5 aut., 20 aut.); The University of Texas M.D Anderson Cancer Center/Houston/Etats-Unis (7 aut., 22 aut.); Department of Epidemiology and Public Health, Yale University School of Medicine/New Haven/Etats-Unis (8 aut., 23 aut.); Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center/New York/Etats-Unis (9 aut.); Toronto General Hospital/Canada (10 aut.); Dalla Lana School of Public Health, University of Toronto/Toronto/Canada (11 aut., 25 aut.); National Institute for Public Health and the Environment (RIVM)/Bilthoven/Pays-Bas (12 aut.); Department of Gastroenterology and Hepatology, University Medical Center Utrecht (UMCU)/Utrecht/Pays-Bas (12 aut., 21 aut.); Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico (CRO)/Aviano/Italie (13 aut., 14 aut.); Epidemiology Research Unit, Research Centre (CRCHUM)/Montreal/Canada (15 aut.); Public Health, Women's and Children's Hospital/Adelaide/Australie (16 aut.); Cancer Center & Institute of Oncology/Warsaw/Pologne (17 aut.); Louisiana State University, School of Public Health/New Orleans/Etats-Unis (18 aut.); Department of Medicine, Memorial Sloan-Kettering Cancer Center/New York/Etats-Unis (24 aut.); Cancer Care Ontario/Toronto/Canada (25 aut.); European Institute of Oncology/Milan/Italie (27 aut.); Catalan Institute of Oncology (ICO)/Barcelona/Espagne (28 aut.); International Prevention Research Institute/Lyon/France (30 aut.); The Tisch Cancer Institute, Mount Sinai School of Medicine/New York/Etats-Unis (30 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Annals of oncology; ISSN 0923-7534; Royaume-Uni; Da. 2011; Vol. 22; No. 6; Pp. 1420-1426; Bibl. 30 ref. |
| LA : | Anglais |
| EA : | Background: Cigarette smoking is the best-characterized risk factor for pancreatic cancer. However, data are limited for other tobacco smoking products and smokeless tobacco. Materials and methods: We conducted a pooled analysis of cigar and pipe smoking and smokeless tobacco use and risk of pancreatic cancer using data from 11 case-control studies (6056 cases and 11 338 controls) within the International Pancreatic Cancer Case-Control Consortium (PanC4). Pooled odds ratios (OR) and the corresponding 95% confidence intervals (CI) were estimated by unconditional multiple logistic regression models adjusted for study center and selected covariates. Results: Compared with never tobacco users, the OR for cigar-only smokers was 1.6 (95% CI: 1.2-2.3), i.e. comparable to that of cigarette-only smokers (OR 1.5; 95% CI 1.4-1.6). The OR was 1.1 (95% CI 0.69-1.6) for pipe-only smokers. There was some evidence of increasing risk with increasing amount of cigar smoked per day (OR 1.82 for ≥ 10 grams of tobacco), although not with duration. The OR for ever smokeless tobacco users as compared with never tobacco users was 0.98 (95% CI 0.75-1.3). Conclusion: This collaborative analysis provides evidence that cigar smoking is associated with an excess risk of pancreatic cancer, while no significant association emerged for pipe smoking and smokeless tobacco use. |
| CC : | 002B02R; 002B03E; 002B13C01 |
| FD : | Cigare; Tabagisme; Tabac sans fumée; Cancer du pancréas; Analyse; International; Homme; Etude cas témoin |
| FG : | Pathologie de l'appareil digestif; Tumeur maligne; Cancer; Pathologie du pancréas |
| ED : | Cigar; Tobacco smoking; Smokeless tobacco; Pancreas cancer; Analysis; International; Human; Case control study |
| EG : | Digestive diseases; Malignant tumor; Cancer; Pancreatic disease |
| SD : | Puro; Tabaquismo; Tabaco sin humo; Cáncer del páncreas; Análisis; Internacional; Hombre; Estudio caso control |
| LO : | INIST-22429.354000190416990240 |
| ID : | 11-0317098 |
Links to Exploration step
Pascal:11-0317098Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4)</title><author><name sortKey="Bertuccio, P" sort="Bertuccio, P" uniqKey="Bertuccio P" first="P." last="Bertuccio">P. Bertuccio</name><affiliation><inist:fA14 i1="01"><s1>Department of Epidemiology, Istituto di Ricerche Farmacologiche "Mario Negri</s1><s2>Milan</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>29 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Department of Occupational Health, Section of Medical Statistics, University of Milan</s1><s2>Milan</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="La Vecchia, C" sort="La Vecchia, C" uniqKey="La Vecchia C" first="C." last="La Vecchia">C. La Vecchia</name><affiliation><inist:fA14 i1="01"><s1>Department of Epidemiology, Istituto di Ricerche Farmacologiche "Mario Negri</s1><s2>Milan</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>29 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Department of Occupational Health, Section of Medical Statistics, University of Milan</s1><s2>Milan</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Silverman, D T" sort="Silverman, D T" uniqKey="Silverman D" first="D. T." last="Silverman">D. T. Silverman</name><affiliation><inist:fA14 i1="03"><s1>National Cancer Institute</s1><s2>Bethesda</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>26 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Petersen, G M" sort="Petersen, G M" uniqKey="Petersen G" first="G. M." last="Petersen">G. M. Petersen</name><affiliation><inist:fA14 i1="04"><s1>Mayo Clinic</s1><s2>Rochester</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>19 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bracci, P M" sort="Bracci, P M" uniqKey="Bracci P" first="P. M." last="Bracci">P. M. Bracci</name><affiliation><inist:fA14 i1="05"><s1>University of California</s1><s2>San Francisco</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Negri, E" sort="Negri, E" uniqKey="Negri E" first="E." last="Negri">E. Negri</name><affiliation><inist:fA14 i1="01"><s1>Department of Epidemiology, Istituto di Ricerche Farmacologiche "Mario Negri</s1><s2>Milan</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>29 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Li, D" sort="Li, D" uniqKey="Li D" first="D." last="Li">D. Li</name><affiliation><inist:fA14 i1="06"><s1>The University of Texas M.D Anderson Cancer Center</s1><s2>Houston</s2><s3>USA</s3><sZ>7 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Risch, H A" sort="Risch, H A" uniqKey="Risch H" first="H. A." last="Risch">H. A. Risch</name><affiliation><inist:fA14 i1="07"><s1>Department of Epidemiology and Public Health, Yale University School of Medicine</s1><s2>New Haven</s2><s3>USA</s3><sZ>8 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Olson, S H" sort="Olson, S H" uniqKey="Olson S" first="S. H." last="Olson">S. H. Olson</name><affiliation><inist:fA14 i1="08"><s1>Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center</s1><s2>New York</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gallinger, S" sort="Gallinger, S" uniqKey="Gallinger S" first="S." last="Gallinger">S. Gallinger</name><affiliation><inist:fA14 i1="09"><s1>Toronto General Hospital</s1><s3>CAN</s3><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Miller, A B" sort="Miller, A B" uniqKey="Miller A" first="A. B." last="Miller">A. B. Miller</name><affiliation><inist:fA14 i1="10"><s1>Dalla Lana School of Public Health, University of Toronto</s1><s2>Toronto</s2><s3>CAN</s3><sZ>11 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bueno De Mesquita, H B" sort="Bueno De Mesquita, H B" uniqKey="Bueno De Mesquita H" first="H. B." last="Bueno-De-Mesquita">H. B. Bueno-De-Mesquita</name><affiliation><inist:fA14 i1="11"><s1>National Institute for Public Health and the Environment (RIVM)</s1><s2>Bilthoven</s2><s3>NLD</s3><sZ>12 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="12"><s1>Department of Gastroenterology and Hepatology, University Medical Center Utrecht (UMCU)</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>12 aut.</sZ><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Talamini, R" sort="Talamini, R" uniqKey="Talamini R" first="R." last="Talamini">R. Talamini</name><affiliation><inist:fA14 i1="13"><s1>Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico (CRO)</s1><s2>Aviano</s2><s3>ITA</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Polesel, J" sort="Polesel, J" uniqKey="Polesel J" first="J." last="Polesel">J. Polesel</name><affiliation><inist:fA14 i1="13"><s1>Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico (CRO)</s1><s2>Aviano</s2><s3>ITA</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ghadirian, P" sort="Ghadirian, P" uniqKey="Ghadirian P" first="P." last="Ghadirian">P. Ghadirian</name><affiliation><inist:fA14 i1="14"><s1>Epidemiology Research Unit, Research Centre (CRCHUM)</s1><s2>Montreal</s2><s3>CAN</s3><sZ>15 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Baghurst, P A" sort="Baghurst, P A" uniqKey="Baghurst P" first="P. A." last="Baghurst">P. A. Baghurst</name><affiliation><inist:fA14 i1="15"><s1>Public Health, Women's and Children's Hospital</s1><s2>Adelaide</s2><s3>AUS</s3><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Zatonski, W" sort="Zatonski, W" uniqKey="Zatonski W" first="W." last="Zatonski">W. Zatonski</name><affiliation><inist:fA14 i1="16"><s1>Cancer Center & Institute of Oncology</s1><s2>Warsaw</s2><s3>POL</s3><sZ>17 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Fontham, E T" sort="Fontham, E T" uniqKey="Fontham E" first="E. T." last="Fontham">E. T. Fontham</name><affiliation><inist:fA14 i1="17"><s1>Louisiana State University, School of Public Health</s1><s2>New Orleans</s2><s3>USA</s3><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bamlet, W R" sort="Bamlet, W R" uniqKey="Bamlet W" first="W. R." last="Bamlet">W. R. Bamlet</name><affiliation><inist:fA14 i1="04"><s1>Mayo Clinic</s1><s2>Rochester</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>19 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Holly, E A" sort="Holly, E A" uniqKey="Holly E" first="E. A." last="Holly">E. A. Holly</name><affiliation><inist:fA14 i1="05"><s1>University of California</s1><s2>San Francisco</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lucenteforte, E" sort="Lucenteforte, E" uniqKey="Lucenteforte E" first="E." last="Lucenteforte">E. Lucenteforte</name><affiliation><inist:fA14 i1="12"><s1>Department of Gastroenterology and Hepatology, University Medical Center Utrecht (UMCU)</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>12 aut.</sZ><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hassan, M" sort="Hassan, M" uniqKey="Hassan M" first="M." last="Hassan">M. Hassan</name><affiliation><inist:fA14 i1="06"><s1>The University of Texas M.D Anderson Cancer Center</s1><s2>Houston</s2><s3>USA</s3><sZ>7 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Yu, H" sort="Yu, H" uniqKey="Yu H" first="H." last="Yu">H. Yu</name><affiliation><inist:fA14 i1="07"><s1>Department of Epidemiology and Public Health, Yale University School of Medicine</s1><s2>New Haven</s2><s3>USA</s3><sZ>8 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kurtz, R C" sort="Kurtz, R C" uniqKey="Kurtz R" first="R. C." last="Kurtz">R. C. Kurtz</name><affiliation><inist:fA14 i1="18"><s1>Department of Medicine, Memorial Sloan-Kettering Cancer Center</s1><s2>New York</s2><s3>USA</s3><sZ>24 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Cotterchio, M" sort="Cotterchio, M" uniqKey="Cotterchio M" first="M." last="Cotterchio">M. Cotterchio</name><affiliation><inist:fA14 i1="10"><s1>Dalla Lana School of Public Health, University of Toronto</s1><s2>Toronto</s2><s3>CAN</s3><sZ>11 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="19"><s1>Cancer Care Ontario</s1><s2>Toronto</s2><s3>CAN</s3><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Su, J" sort="Su, J" uniqKey="Su J" first="J." last="Su">J. Su</name><affiliation><inist:fA14 i1="03"><s1>National Cancer Institute</s1><s2>Bethesda</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>26 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Maisonneuve, P" sort="Maisonneuve, P" uniqKey="Maisonneuve P" first="P." last="Maisonneuve">P. Maisonneuve</name><affiliation><inist:fA14 i1="20"><s1>European Institute of Oncology</s1><s2>Milan</s2><s3>ITA</s3><sZ>27 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Duell, E J" sort="Duell, E J" uniqKey="Duell E" first="E. J." last="Duell">E. J. Duell</name><affiliation><inist:fA14 i1="21"><s1>Catalan Institute of Oncology (ICO)</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>28 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bosetti, C" sort="Bosetti, C" uniqKey="Bosetti C" first="C." last="Bosetti">C. Bosetti</name><affiliation><inist:fA14 i1="01"><s1>Department of Epidemiology, Istituto di Ricerche Farmacologiche "Mario Negri</s1><s2>Milan</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>29 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Boffetta, P" sort="Boffetta, P" uniqKey="Boffetta P" first="P." last="Boffetta">P. Boffetta</name><affiliation><inist:fA14 i1="22"><s1>International Prevention Research Institute</s1><s2>Lyon</s2><s3>FRA</s3><sZ>30 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="23"><s1>The Tisch Cancer Institute, Mount Sinai School of Medicine</s1><s2>New York</s2><s3>USA</s3><sZ>30 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0317098</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 11-0317098 INIST</idno><idno type="RBID">Pascal:11-0317098</idno><idno type="wicri:Area/PascalFrancis/Corpus">001B15</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4)</title><author><name sortKey="Bertuccio, P" sort="Bertuccio, P" uniqKey="Bertuccio P" first="P." last="Bertuccio">P. Bertuccio</name><affiliation><inist:fA14 i1="01"><s1>Department of Epidemiology, Istituto di Ricerche Farmacologiche "Mario Negri</s1><s2>Milan</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>29 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Department of Occupational Health, Section of Medical Statistics, University of Milan</s1><s2>Milan</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="La Vecchia, C" sort="La Vecchia, C" uniqKey="La Vecchia C" first="C." last="La Vecchia">C. La Vecchia</name><affiliation><inist:fA14 i1="01"><s1>Department of Epidemiology, Istituto di Ricerche Farmacologiche "Mario Negri</s1><s2>Milan</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>29 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Department of Occupational Health, Section of Medical Statistics, University of Milan</s1><s2>Milan</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Silverman, D T" sort="Silverman, D T" uniqKey="Silverman D" first="D. T." last="Silverman">D. T. Silverman</name><affiliation><inist:fA14 i1="03"><s1>National Cancer Institute</s1><s2>Bethesda</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>26 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Petersen, G M" sort="Petersen, G M" uniqKey="Petersen G" first="G. M." last="Petersen">G. M. Petersen</name><affiliation><inist:fA14 i1="04"><s1>Mayo Clinic</s1><s2>Rochester</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>19 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bracci, P M" sort="Bracci, P M" uniqKey="Bracci P" first="P. M." last="Bracci">P. M. Bracci</name><affiliation><inist:fA14 i1="05"><s1>University of California</s1><s2>San Francisco</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Negri, E" sort="Negri, E" uniqKey="Negri E" first="E." last="Negri">E. Negri</name><affiliation><inist:fA14 i1="01"><s1>Department of Epidemiology, Istituto di Ricerche Farmacologiche "Mario Negri</s1><s2>Milan</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>29 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Li, D" sort="Li, D" uniqKey="Li D" first="D." last="Li">D. Li</name><affiliation><inist:fA14 i1="06"><s1>The University of Texas M.D Anderson Cancer Center</s1><s2>Houston</s2><s3>USA</s3><sZ>7 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Risch, H A" sort="Risch, H A" uniqKey="Risch H" first="H. A." last="Risch">H. A. Risch</name><affiliation><inist:fA14 i1="07"><s1>Department of Epidemiology and Public Health, Yale University School of Medicine</s1><s2>New Haven</s2><s3>USA</s3><sZ>8 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Olson, S H" sort="Olson, S H" uniqKey="Olson S" first="S. H." last="Olson">S. H. Olson</name><affiliation><inist:fA14 i1="08"><s1>Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center</s1><s2>New York</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gallinger, S" sort="Gallinger, S" uniqKey="Gallinger S" first="S." last="Gallinger">S. Gallinger</name><affiliation><inist:fA14 i1="09"><s1>Toronto General Hospital</s1><s3>CAN</s3><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Miller, A B" sort="Miller, A B" uniqKey="Miller A" first="A. B." last="Miller">A. B. Miller</name><affiliation><inist:fA14 i1="10"><s1>Dalla Lana School of Public Health, University of Toronto</s1><s2>Toronto</s2><s3>CAN</s3><sZ>11 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bueno De Mesquita, H B" sort="Bueno De Mesquita, H B" uniqKey="Bueno De Mesquita H" first="H. B." last="Bueno-De-Mesquita">H. B. Bueno-De-Mesquita</name><affiliation><inist:fA14 i1="11"><s1>National Institute for Public Health and the Environment (RIVM)</s1><s2>Bilthoven</s2><s3>NLD</s3><sZ>12 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="12"><s1>Department of Gastroenterology and Hepatology, University Medical Center Utrecht (UMCU)</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>12 aut.</sZ><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Talamini, R" sort="Talamini, R" uniqKey="Talamini R" first="R." last="Talamini">R. Talamini</name><affiliation><inist:fA14 i1="13"><s1>Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico (CRO)</s1><s2>Aviano</s2><s3>ITA</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Polesel, J" sort="Polesel, J" uniqKey="Polesel J" first="J." last="Polesel">J. Polesel</name><affiliation><inist:fA14 i1="13"><s1>Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico (CRO)</s1><s2>Aviano</s2><s3>ITA</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ghadirian, P" sort="Ghadirian, P" uniqKey="Ghadirian P" first="P." last="Ghadirian">P. Ghadirian</name><affiliation><inist:fA14 i1="14"><s1>Epidemiology Research Unit, Research Centre (CRCHUM)</s1><s2>Montreal</s2><s3>CAN</s3><sZ>15 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Baghurst, P A" sort="Baghurst, P A" uniqKey="Baghurst P" first="P. A." last="Baghurst">P. A. Baghurst</name><affiliation><inist:fA14 i1="15"><s1>Public Health, Women's and Children's Hospital</s1><s2>Adelaide</s2><s3>AUS</s3><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Zatonski, W" sort="Zatonski, W" uniqKey="Zatonski W" first="W." last="Zatonski">W. Zatonski</name><affiliation><inist:fA14 i1="16"><s1>Cancer Center & Institute of Oncology</s1><s2>Warsaw</s2><s3>POL</s3><sZ>17 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Fontham, E T" sort="Fontham, E T" uniqKey="Fontham E" first="E. T." last="Fontham">E. T. Fontham</name><affiliation><inist:fA14 i1="17"><s1>Louisiana State University, School of Public Health</s1><s2>New Orleans</s2><s3>USA</s3><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bamlet, W R" sort="Bamlet, W R" uniqKey="Bamlet W" first="W. R." last="Bamlet">W. R. Bamlet</name><affiliation><inist:fA14 i1="04"><s1>Mayo Clinic</s1><s2>Rochester</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>19 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Holly, E A" sort="Holly, E A" uniqKey="Holly E" first="E. A." last="Holly">E. A. Holly</name><affiliation><inist:fA14 i1="05"><s1>University of California</s1><s2>San Francisco</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lucenteforte, E" sort="Lucenteforte, E" uniqKey="Lucenteforte E" first="E." last="Lucenteforte">E. Lucenteforte</name><affiliation><inist:fA14 i1="12"><s1>Department of Gastroenterology and Hepatology, University Medical Center Utrecht (UMCU)</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>12 aut.</sZ><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hassan, M" sort="Hassan, M" uniqKey="Hassan M" first="M." last="Hassan">M. Hassan</name><affiliation><inist:fA14 i1="06"><s1>The University of Texas M.D Anderson Cancer Center</s1><s2>Houston</s2><s3>USA</s3><sZ>7 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Yu, H" sort="Yu, H" uniqKey="Yu H" first="H." last="Yu">H. Yu</name><affiliation><inist:fA14 i1="07"><s1>Department of Epidemiology and Public Health, Yale University School of Medicine</s1><s2>New Haven</s2><s3>USA</s3><sZ>8 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kurtz, R C" sort="Kurtz, R C" uniqKey="Kurtz R" first="R. C." last="Kurtz">R. C. Kurtz</name><affiliation><inist:fA14 i1="18"><s1>Department of Medicine, Memorial Sloan-Kettering Cancer Center</s1><s2>New York</s2><s3>USA</s3><sZ>24 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Cotterchio, M" sort="Cotterchio, M" uniqKey="Cotterchio M" first="M." last="Cotterchio">M. Cotterchio</name><affiliation><inist:fA14 i1="10"><s1>Dalla Lana School of Public Health, University of Toronto</s1><s2>Toronto</s2><s3>CAN</s3><sZ>11 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="19"><s1>Cancer Care Ontario</s1><s2>Toronto</s2><s3>CAN</s3><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Su, J" sort="Su, J" uniqKey="Su J" first="J." last="Su">J. Su</name><affiliation><inist:fA14 i1="03"><s1>National Cancer Institute</s1><s2>Bethesda</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>26 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Maisonneuve, P" sort="Maisonneuve, P" uniqKey="Maisonneuve P" first="P." last="Maisonneuve">P. Maisonneuve</name><affiliation><inist:fA14 i1="20"><s1>European Institute of Oncology</s1><s2>Milan</s2><s3>ITA</s3><sZ>27 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Duell, E J" sort="Duell, E J" uniqKey="Duell E" first="E. J." last="Duell">E. J. Duell</name><affiliation><inist:fA14 i1="21"><s1>Catalan Institute of Oncology (ICO)</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>28 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bosetti, C" sort="Bosetti, C" uniqKey="Bosetti C" first="C." last="Bosetti">C. Bosetti</name><affiliation><inist:fA14 i1="01"><s1>Department of Epidemiology, Istituto di Ricerche Farmacologiche "Mario Negri</s1><s2>Milan</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>29 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Boffetta, P" sort="Boffetta, P" uniqKey="Boffetta P" first="P." last="Boffetta">P. Boffetta</name><affiliation><inist:fA14 i1="22"><s1>International Prevention Research Institute</s1><s2>Lyon</s2><s3>FRA</s3><sZ>30 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="23"><s1>The Tisch Cancer Institute, Mount Sinai School of Medicine</s1><s2>New York</s2><s3>USA</s3><sZ>30 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Annals of oncology</title><title level="j" type="abbreviated">Ann. oncol.</title><idno type="ISSN">0923-7534</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Annals of oncology</title><title level="j" type="abbreviated">Ann. oncol.</title><idno type="ISSN">0923-7534</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis</term><term>Case control study</term><term>Cigar</term><term>Human</term><term>International</term><term>Pancreas cancer</term><term>Smokeless tobacco</term><term>Tobacco smoking</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Cigare</term><term>Tabagisme</term><term>Tabac sans fumée</term><term>Cancer du pancréas</term><term>Analyse</term><term>International</term><term>Homme</term><term>Etude cas témoin</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Cigarette smoking is the best-characterized risk factor for pancreatic cancer. However, data are limited for other tobacco smoking products and smokeless tobacco. Materials and methods: We conducted a pooled analysis of cigar and pipe smoking and smokeless tobacco use and risk of pancreatic cancer using data from 11 case-control studies (6056 cases and 11 338 controls) within the International Pancreatic Cancer Case-Control Consortium (PanC4). Pooled odds ratios (OR) and the corresponding 95% confidence intervals (CI) were estimated by unconditional multiple logistic regression models adjusted for study center and selected covariates. Results: Compared with never tobacco users, the OR for cigar-only smokers was 1.6 (95% CI: 1.2-2.3), i.e. comparable to that of cigarette-only smokers (OR 1.5; 95% CI 1.4-1.6). The OR was 1.1 (95% CI 0.69-1.6) for pipe-only smokers. There was some evidence of increasing risk with increasing amount of cigar smoked per day (OR 1.82 for ≥ 10 grams of tobacco), although not with duration. The OR for ever smokeless tobacco users as compared with never tobacco users was 0.98 (95% CI 0.75-1.3). Conclusion: This collaborative analysis provides evidence that cigar smoking is associated with an excess risk of pancreatic cancer, while no significant association emerged for pipe smoking and smokeless tobacco use.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0923-7534</s0></fA01><fA03 i2="1"><s0>Ann. oncol.</s0></fA03><fA05><s2>22</s2></fA05><fA06><s2>6</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4)</s1></fA08><fA11 i1="01" i2="1"><s1>BERTUCCIO (P.)</s1></fA11><fA11 i1="02" i2="1"><s1>LA VECCHIA (C.)</s1></fA11><fA11 i1="03" i2="1"><s1>SILVERMAN (D. T.)</s1></fA11><fA11 i1="04" i2="1"><s1>PETERSEN (G. M.)</s1></fA11><fA11 i1="05" i2="1"><s1>BRACCI (P. M.)</s1></fA11><fA11 i1="06" i2="1"><s1>NEGRI (E.)</s1></fA11><fA11 i1="07" i2="1"><s1>LI (D.)</s1></fA11><fA11 i1="08" i2="1"><s1>RISCH (H. A.)</s1></fA11><fA11 i1="09" i2="1"><s1>OLSON (S. H.)</s1></fA11><fA11 i1="10" i2="1"><s1>GALLINGER (S.)</s1></fA11><fA11 i1="11" i2="1"><s1>MILLER (A. B.)</s1></fA11><fA11 i1="12" i2="1"><s1>BUENO-DE-MESQUITA (H. B.)</s1></fA11><fA11 i1="13" i2="1"><s1>TALAMINI (R.)</s1></fA11><fA11 i1="14" i2="1"><s1>POLESEL (J.)</s1></fA11><fA11 i1="15" i2="1"><s1>GHADIRIAN (P.)</s1></fA11><fA11 i1="16" i2="1"><s1>BAGHURST (P. A.)</s1></fA11><fA11 i1="17" i2="1"><s1>ZATONSKI (W.)</s1></fA11><fA11 i1="18" i2="1"><s1>FONTHAM (E. T.)</s1></fA11><fA11 i1="19" i2="1"><s1>BAMLET (W. R.)</s1></fA11><fA11 i1="20" i2="1"><s1>HOLLY (E. A.)</s1></fA11><fA11 i1="21" i2="1"><s1>LUCENTEFORTE (E.)</s1></fA11><fA11 i1="22" i2="1"><s1>HASSAN (M.)</s1></fA11><fA11 i1="23" i2="1"><s1>YU (H.)</s1></fA11><fA11 i1="24" i2="1"><s1>KURTZ (R. C.)</s1></fA11><fA11 i1="25" i2="1"><s1>COTTERCHIO (M.)</s1></fA11><fA11 i1="26" i2="1"><s1>SU (J.)</s1></fA11><fA11 i1="27" i2="1"><s1>MAISONNEUVE (P.)</s1></fA11><fA11 i1="28" i2="1"><s1>DUELL (E. J.)</s1></fA11><fA11 i1="29" i2="1"><s1>BOSETTI (C.)</s1></fA11><fA11 i1="30" i2="1"><s1>BOFFETTA (P.)</s1></fA11><fA14 i1="01"><s1>Department of Epidemiology, Istituto di Ricerche Farmacologiche "Mario Negri</s1><s2>Milan</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>29 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Occupational Health, Section of Medical Statistics, University of Milan</s1><s2>Milan</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>National Cancer Institute</s1><s2>Bethesda</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>26 aut.</sZ></fA14><fA14 i1="04"><s1>Mayo Clinic</s1><s2>Rochester</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>19 aut.</sZ></fA14><fA14 i1="05"><s1>University of California</s1><s2>San Francisco</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>20 aut.</sZ></fA14><fA14 i1="06"><s1>The University of Texas M.D Anderson Cancer Center</s1><s2>Houston</s2><s3>USA</s3><sZ>7 aut.</sZ><sZ>22 aut.</sZ></fA14><fA14 i1="07"><s1>Department of Epidemiology and Public Health, Yale University School of Medicine</s1><s2>New Haven</s2><s3>USA</s3><sZ>8 aut.</sZ><sZ>23 aut.</sZ></fA14><fA14 i1="08"><s1>Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center</s1><s2>New York</s2><s3>USA</s3><sZ>9 aut.</sZ></fA14><fA14 i1="09"><s1>Toronto General Hospital</s1><s3>CAN</s3><sZ>10 aut.</sZ></fA14><fA14 i1="10"><s1>Dalla Lana School of Public Health, University of Toronto</s1><s2>Toronto</s2><s3>CAN</s3><sZ>11 aut.</sZ><sZ>25 aut.</sZ></fA14><fA14 i1="11"><s1>National Institute for Public Health and the Environment (RIVM)</s1><s2>Bilthoven</s2><s3>NLD</s3><sZ>12 aut.</sZ></fA14><fA14 i1="12"><s1>Department of Gastroenterology and Hepatology, University Medical Center Utrecht (UMCU)</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>12 aut.</sZ><sZ>21 aut.</sZ></fA14><fA14 i1="13"><s1>Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico (CRO)</s1><s2>Aviano</s2><s3>ITA</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></fA14><fA14 i1="14"><s1>Epidemiology Research Unit, Research Centre (CRCHUM)</s1><s2>Montreal</s2><s3>CAN</s3><sZ>15 aut.</sZ></fA14><fA14 i1="15"><s1>Public Health, Women's and Children's Hospital</s1><s2>Adelaide</s2><s3>AUS</s3><sZ>16 aut.</sZ></fA14><fA14 i1="16"><s1>Cancer Center & Institute of Oncology</s1><s2>Warsaw</s2><s3>POL</s3><sZ>17 aut.</sZ></fA14><fA14 i1="17"><s1>Louisiana State University, School of Public Health</s1><s2>New Orleans</s2><s3>USA</s3><sZ>18 aut.</sZ></fA14><fA14 i1="18"><s1>Department of Medicine, Memorial Sloan-Kettering Cancer Center</s1><s2>New York</s2><s3>USA</s3><sZ>24 aut.</sZ></fA14><fA14 i1="19"><s1>Cancer Care Ontario</s1><s2>Toronto</s2><s3>CAN</s3><sZ>25 aut.</sZ></fA14><fA14 i1="20"><s1>European Institute of Oncology</s1><s2>Milan</s2><s3>ITA</s3><sZ>27 aut.</sZ></fA14><fA14 i1="21"><s1>Catalan Institute of Oncology (ICO)</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>28 aut.</sZ></fA14><fA14 i1="22"><s1>International Prevention Research Institute</s1><s2>Lyon</s2><s3>FRA</s3><sZ>30 aut.</sZ></fA14><fA14 i1="23"><s1>The Tisch Cancer Institute, Mount Sinai School of Medicine</s1><s2>New York</s2><s3>USA</s3><sZ>30 aut.</sZ></fA14><fA20><s1>1420-1426</s1></fA20><fA21><s1>2011</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>22429</s2><s5>354000190416990240</s5></fA43><fA44><s0>0000</s0><s1>© 2011 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>30 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>11-0317098</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Annals of oncology</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Background: Cigarette smoking is the best-characterized risk factor for pancreatic cancer. However, data are limited for other tobacco smoking products and smokeless tobacco. Materials and methods: We conducted a pooled analysis of cigar and pipe smoking and smokeless tobacco use and risk of pancreatic cancer using data from 11 case-control studies (6056 cases and 11 338 controls) within the International Pancreatic Cancer Case-Control Consortium (PanC4). Pooled odds ratios (OR) and the corresponding 95% confidence intervals (CI) were estimated by unconditional multiple logistic regression models adjusted for study center and selected covariates. Results: Compared with never tobacco users, the OR for cigar-only smokers was 1.6 (95% CI: 1.2-2.3), i.e. comparable to that of cigarette-only smokers (OR 1.5; 95% CI 1.4-1.6). The OR was 1.1 (95% CI 0.69-1.6) for pipe-only smokers. There was some evidence of increasing risk with increasing amount of cigar smoked per day (OR 1.82 for ≥ 10 grams of tobacco), although not with duration. The OR for ever smokeless tobacco users as compared with never tobacco users was 0.98 (95% CI 0.75-1.3). Conclusion: This collaborative analysis provides evidence that cigar smoking is associated with an excess risk of pancreatic cancer, while no significant association emerged for pipe smoking and smokeless tobacco use.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02R</s0></fC02><fC02 i1="02" i2="X"><s0>002B03E</s0></fC02><fC02 i1="03" i2="X"><s0>002B13C01</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Cigare</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Cigar</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Puro</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Tabagisme</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Tobacco smoking</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Tabaquismo</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Tabac sans fumée</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Smokeless tobacco</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Tabaco sin humo</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Cancer du pancréas</s0><s2>NM</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Pancreas cancer</s0><s2>NM</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Cáncer del páncreas</s0><s2>NM</s2><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Analyse</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Analysis</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Análisis</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>International</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>International</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Internacional</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Human</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Etude cas témoin</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Case control study</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Estudio caso control</s0><s5>08</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'appareil digestif</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Digestive diseases</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Aparato digestivo patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Tumeur maligne</s0><s2>NM</s2><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Malignant tumor</s0><s2>NM</s2><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Tumor maligno</s0><s2>NM</s2><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Cáncer</s0><s2>NM</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du pancréas</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Pancreatic disease</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Páncreas patología</s0><s5>39</s5></fC07><fN21><s1>213</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 11-0317098 INIST</NO><ET>Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4)</ET><AU>BERTUCCIO (P.); LA VECCHIA (C.); SILVERMAN (D. T.); PETERSEN (G. M.); BRACCI (P. M.); NEGRI (E.); LI (D.); RISCH (H. A.); OLSON (S. H.); GALLINGER (S.); MILLER (A. B.); BUENO-DE-MESQUITA (H. B.); TALAMINI (R.); POLESEL (J.); GHADIRIAN (P.); BAGHURST (P. A.); ZATONSKI (W.); FONTHAM (E. T.); BAMLET (W. R.); HOLLY (E. A.); LUCENTEFORTE (E.); HASSAN (M.); YU (H.); KURTZ (R. C.); COTTERCHIO (M.); SU (J.); MAISONNEUVE (P.); DUELL (E. J.); BOSETTI (C.); BOFFETTA (P.)</AU><AF>Department of Epidemiology, Istituto di Ricerche Farmacologiche "Mario Negri/Milan/Italie (1 aut., 2 aut., 6 aut., 29 aut.); Department of Occupational Health, Section of Medical Statistics, University of Milan/Milan/Italie (1 aut., 2 aut.); National Cancer Institute/Bethesda/Etats-Unis (3 aut., 26 aut.); Mayo Clinic/Rochester/Etats-Unis (4 aut., 19 aut.); University of California/San Francisco/Etats-Unis (5 aut., 20 aut.); The University of Texas M.D Anderson Cancer Center/Houston/Etats-Unis (7 aut., 22 aut.); Department of Epidemiology and Public Health, Yale University School of Medicine/New Haven/Etats-Unis (8 aut., 23 aut.); Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center/New York/Etats-Unis (9 aut.); Toronto General Hospital/Canada (10 aut.); Dalla Lana School of Public Health, University of Toronto/Toronto/Canada (11 aut., 25 aut.); National Institute for Public Health and the Environment (RIVM)/Bilthoven/Pays-Bas (12 aut.); Department of Gastroenterology and Hepatology, University Medical Center Utrecht (UMCU)/Utrecht/Pays-Bas (12 aut., 21 aut.); Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico (CRO)/Aviano/Italie (13 aut., 14 aut.); Epidemiology Research Unit, Research Centre (CRCHUM)/Montreal/Canada (15 aut.); Public Health, Women's and Children's Hospital/Adelaide/Australie (16 aut.); Cancer Center & Institute of Oncology/Warsaw/Pologne (17 aut.); Louisiana State University, School of Public Health/New Orleans/Etats-Unis (18 aut.); Department of Medicine, Memorial Sloan-Kettering Cancer Center/New York/Etats-Unis (24 aut.); Cancer Care Ontario/Toronto/Canada (25 aut.); European Institute of Oncology/Milan/Italie (27 aut.); Catalan Institute of Oncology (ICO)/Barcelona/Espagne (28 aut.); International Prevention Research Institute/Lyon/France (30 aut.); The Tisch Cancer Institute, Mount Sinai School of Medicine/New York/Etats-Unis (30 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Annals of oncology; ISSN 0923-7534; Royaume-Uni; Da. 2011; Vol. 22; No. 6; Pp. 1420-1426; Bibl. 30 ref.</SO><LA>Anglais</LA><EA>Background: Cigarette smoking is the best-characterized risk factor for pancreatic cancer. However, data are limited for other tobacco smoking products and smokeless tobacco. Materials and methods: We conducted a pooled analysis of cigar and pipe smoking and smokeless tobacco use and risk of pancreatic cancer using data from 11 case-control studies (6056 cases and 11 338 controls) within the International Pancreatic Cancer Case-Control Consortium (PanC4). Pooled odds ratios (OR) and the corresponding 95% confidence intervals (CI) were estimated by unconditional multiple logistic regression models adjusted for study center and selected covariates. Results: Compared with never tobacco users, the OR for cigar-only smokers was 1.6 (95% CI: 1.2-2.3), i.e. comparable to that of cigarette-only smokers (OR 1.5; 95% CI 1.4-1.6). The OR was 1.1 (95% CI 0.69-1.6) for pipe-only smokers. There was some evidence of increasing risk with increasing amount of cigar smoked per day (OR 1.82 for ≥ 10 grams of tobacco), although not with duration. The OR for ever smokeless tobacco users as compared with never tobacco users was 0.98 (95% CI 0.75-1.3). Conclusion: This collaborative analysis provides evidence that cigar smoking is associated with an excess risk of pancreatic cancer, while no significant association emerged for pipe smoking and smokeless tobacco use.</EA><CC>002B02R; 002B03E; 002B13C01</CC><FD>Cigare; Tabagisme; Tabac sans fumée; Cancer du pancréas; Analyse; International; Homme; Etude cas témoin</FD><FG>Pathologie de l'appareil digestif; Tumeur maligne; Cancer; Pathologie du pancréas</FG><ED>Cigar; Tobacco smoking; Smokeless tobacco; Pancreas cancer; Analysis; International; Human; Case control study</ED><EG>Digestive diseases; Malignant tumor; Cancer; Pancreatic disease</EG><SD>Puro; Tabaquismo; Tabaco sin humo; Cáncer del páncreas; Análisis; Internacional; Hombre; Estudio caso control</SD><LO>INIST-22429.354000190416990240</LO><ID>11-0317098</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B15 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001B15 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:11-0317098
|texte= Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4)
}}
| This area was generated with Dilib version V0.6.33. |  |